I feel your pain. It is hard to refer anyone
Post# of 154130
(Total Views: 721)
Posted On: 05/03/2020 10:31:08 AM
I feel your pain.
It is hard to refer anyone to this company/drug without them having to sift through -- not just useless noise -- but the frequently moronic and manipulative posts found on a surprisingly large number of boards.
Even articles and comments on Seeking Alpha have this very unfortunate component. It is very difficult for anyone new to the company/drug to navigate through this trash, and moreover, it absolutely does not instill confidence in the legitimacy of the company/drug.
For myriad reasons that don't need to be repeated, CytoDyn has been fighting an identity crisis for many years -- not in the way that it perceives itself -- but in the way that others perceive it.
A COVID approval will represent an inflection point that will change that perception problem permanently. I still anticipate there will still be challenges with the FDA, as it is a corrupt regulating body that is so obviously in the pocket of Big Pharma. However, it will be harder for them to slow-walk CytoDyn in the future.
I believe Big Pharma is (and will be) very threatened by leronlimab. And, it's not just Big Pharma -- leronlimab has the ability to derail all manner of pre-clinical and clinical stage investigations by small and medium biotechs. If we are lucky enough to move forward and gain traction, I see leronlimab as potentially being one of the biggest disruptive drugs to hit the market.
I hope/suspect that Dr. Patterson's paper will eventually push many of those trash search results down to lower Google pages. It's just a matter of time.
It is hard to refer anyone to this company/drug without them having to sift through -- not just useless noise -- but the frequently moronic and manipulative posts found on a surprisingly large number of boards.
Even articles and comments on Seeking Alpha have this very unfortunate component. It is very difficult for anyone new to the company/drug to navigate through this trash, and moreover, it absolutely does not instill confidence in the legitimacy of the company/drug.
For myriad reasons that don't need to be repeated, CytoDyn has been fighting an identity crisis for many years -- not in the way that it perceives itself -- but in the way that others perceive it.
A COVID approval will represent an inflection point that will change that perception problem permanently. I still anticipate there will still be challenges with the FDA, as it is a corrupt regulating body that is so obviously in the pocket of Big Pharma. However, it will be harder for them to slow-walk CytoDyn in the future.
I believe Big Pharma is (and will be) very threatened by leronlimab. And, it's not just Big Pharma -- leronlimab has the ability to derail all manner of pre-clinical and clinical stage investigations by small and medium biotechs. If we are lucky enough to move forward and gain traction, I see leronlimab as potentially being one of the biggest disruptive drugs to hit the market.
I hope/suspect that Dr. Patterson's paper will eventually push many of those trash search results down to lower Google pages. It's just a matter of time.
(10)
(0)